ClinicalTrials.gg

Program

icovamenib

Also written as “BMF-219”, “icovamenib 100 mg” and “icovamenib 100mg”.

Its studies are mostly in Diabetes Mellitus, Type 2 · Diabetes Mellitus, Type 1 · Leukemia, Myeloid, Acute · Carcinoma, Non-Small-Cell Lung, led by Biomea Fusion.

Furthest: phase 2, since Dec 26, 20227 company-led studies, 2 open or runningNext primary completion: Mar 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Biomea Fusion72 open or runningphase 2since Dec 26, 2022Nov 30, 2021Mar 2027phase 2 · NCT07502495

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 30, 2021First study: phase 1 study in Leukemia, Myeloid, AcuteFirst studyNCT05153330 · 55 enrolled · United States, Greece, Italy and more
  2. Nov 4, 2022Phase 1 study in Carcinoma, Non-Small-Cell LungNCT05631574 · 13 enrolled · United States, Korea, Republic of
  3. Dec 26, 2022Phase 2 study in Diabetes Mellitus, Type 2NCT05731544 · 443 enrolled · United States, Canada
  4. Nov 10, 2023Phase 2 study in Diabetes Mellitus, Type 1NCT06152042 · 37 enrolled · United States, Canada
  5. Oct 10, 2025Phase 1 study in Healthy VolunteerNCT07254286 · 60 enrolled · United States
  6. Mar 26, 20262 phase 2 studies in Diabetes Mellitus, Type 2NCT07502508, NCT07502495

Ahead

  1. Mar 2027Primary completion: phase 2 study in Diabetes Mellitus, Type 2NCT07502495
  2. Jun 2027Primary completion: phase 2 study in Diabetes Mellitus, Type 2NCT07502508

TargetBeta

KMT2A →read by rule
“An orally bioavailable, irriversible inhibitor of menin, an essential co-factor of oncogenic menin-mixed lineage leukemia (MLL; myeloid/lymphoid leukemia; KMT2A) fusion proteins, ”NCIt, by rule

Other programs on KMT2A

ProgramCompanyFurthest phaseStudies
revumenibruleSyndax Pharmaceuticalsphase 36
ziftomenibrulekura-oncology-incphase 36
bleximenibJohnson & Johnsonphase 34

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07502508Diabetes Mellitus, Type 2 · United States2RecruitingJun 202760
NCT07502495Diabetes Mellitus, Type 2 · United States2Active, not recruitingMar 202764
NCT07254286Healthy Volunteer · United States1CompletedJan 14, 202660
NCT06152042Diabetes Mellitus, Type 1 · United States, Canada2CompletedMay 20, 202537
NCT05731544Diabetes Mellitus, Type 2 · United States, Canada2CompletedNov 18, 2024443
NCT05631574Carcinoma, Non-Small-Cell Lung · United States, Korea, Republic of1TerminatedJan 15, 202513
NCT05153330Leukemia, Myeloid, Acute · United States, Greece, Italy and more1TerminatedFeb 13, 202555

How it is read

Names in the registry

  • “BMF-219”, 4 entries
  • “icovamenib 100 mg”, 1 entry
  • “icovamenib 100mg”, 1 entry
  • “Icovamenib”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.